First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment.

Details

Ressource 1Download: 27927678_BIB_E4AC4FB222A2.pdf (480.77 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_E4AC4FB222A2
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment.
Journal
The British journal of ophthalmology
Author(s)
Munier F.L., Mosimann P., Puccinelli F., Gaillard M.C., Stathopoulos C., Houghton S., Bergin C., Beck-Popovic M.
ISSN
1468-2079 (Electronic)
ISSN-L
0007-1161
Publication state
Published
Issued date
08/2017
Peer-reviewed
Oui
Volume
101
Number
8
Pages
1086-1093
Language
english
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Abstract
The introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC.
This is a retrospective mono-centric comparative review of consecutive patients.
Sporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy.
48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality.
Outcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2-218.6) and 41.7 months (range 19.6-89.5), respectively. Treatment duration was significantly shorter in the IAC group (p<0.001). Ten eyes in the IVC group underwent enucleation. Recordable visual acuity of the salvaged eyes was significantly better in the IAC group (0.9 vs 1.4 logarithm of the minimum angle of resolution, p<0.01). No extraocular disease, metastases or long-term systemic complications were observed in either group.
The difference in the time frame between treatment groups had an impact on the availability of intravitreal chemotherapy treatment. Despite this, the results reported here imply that eyes treated with first-line IAC will have shorter treatment period, better ocular survival and visual acuity than first-line IVC.

Keywords
Aftercare, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Carboplatin/administration & dosage, Child, Child, Preschool, Etoposide/administration & dosage, Humans, Infant, Infusions, Intra-Arterial, Infusions, Intravenous, Melphalan/administration & dosage, Retinal Neoplasms/drug therapy, Retinoblastoma/drug therapy, Retrospective Studies, Salvage Therapy/methods, Treatment Outcome, Vision Disorders/prevention & control, Child health (paediatrics), Neoplasia, Retina, Treatment Medical
Pubmed
Web of science
Open Access
Yes
Create date
09/12/2016 15:24
Last modification date
20/08/2019 16:08
Usage data